Lyell Immunopharma, Inc. reported its financial results for the second quarter of 2026, revealing a modest revenue of $4,000, a decrease from $8,000 in the same period last year. For the first half of 2026, revenue totaled $6,000, down from $15,000 in the first half of 2025. The company continues to operate at a loss, with a net loss of $44.8 million for the second quarter, compared to a loss of $42.7 million in the prior year. The total net loss for the first half of 2026 was $68.9 million, an improvement from $94.9 million in the same period of 2025.
Operating expenses for the second quarter were $47.3 million, slightly higher than the $47.1 million reported in the same quarter of 2025. Research and development expenses increased to $39.5 million from $34.9 million year-over-year, primarily due to heightened clinical trial activities. General and administrative expenses decreased to $9.6 million from $9.8 million, reflecting cost management efforts. The company also reported a significant gain of $17.6 million from the change in fair value of its SPA put/call liability, contributing to a total other income of $2.6 million for the quarter.
In terms of strategic developments, Lyell Immunopharma has made significant strides in its clinical pipeline, particularly with its lead product candidate, rondecabtagene autoleucel (ronde-cel), which is currently undergoing pivotal trials for large B-cell lymphoma. The company has also expanded its portfolio with the acquisition of LYL273, a novel CAR T-cell therapy targeting metastatic colorectal cancer, which is in a Phase 1 clinical trial. The company anticipates reporting additional data from these trials in the latter half of 2026.
Operationally, Lyell Immunopharma has maintained a workforce of approximately 300 employees as of June 30, 2026, a slight reduction from previous periods due to the successful technology transfer of its manufacturing processes. The company’s cash and cash equivalents stood at $73.0 million, with total assets amounting to $311.2 million. The company has indicated that it has sufficient liquidity to fund its operations for at least the next 12 months, although it will likely need to raise additional capital to support ongoing research and development efforts.
Looking ahead, Lyell Immunopharma remains focused on advancing its clinical programs and expects to continue incurring significant operating losses as it seeks to bring its innovative therapies to market. The company is actively exploring various funding opportunities to support its growth and operational needs, while also navigating the challenges posed by the current macroeconomic environment.
About Lyell Immunopharma, Inc.
Lyell Immunopharma is a biopharmaceutical company specializing in developing next-generation autologous CAR T-cell therapies for cancer. Its focus includes hematologic malignancies like B-cell lymphomas and solid tumors, utilizing proprietary technologies to enhance T-cell potency, durability, and resistance to exhaustion. The company owns manufacturing facilities and a robust intellectual property portfolio, aiming to deliver innovative, long-lasting cancer treatments through strategic collaborations and advanced cell therapy platforms.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov